Sakar Healthcare Q1 FY27: Revenue INR73cr, PAT up 120%, oncology FY27 target doubled

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedAnalyst Day Multiyear TargetsInvestor Communications View source PDF Explain this filing

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+3.5%1-day move

₹887.00

prior close

₹918.35

base price

In-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.6+0.8——+3.5-0.2+3.8+5.1+2.6+5.7————

Up moveDown movePending

AI summary

Sakar Healthcare Q1 FY27 revenue INR72.97cr, up 38% YoY. EBITDA INR21.25cr, margin 29%. PAT INR10.28cr, up 120%. Oncology Q1 revenue INR33cr. Management guided oncology revenue to double in FY27 and triple in FY28 to around INR280-300cr. Full company FY27 revenue guidance around INR350cr. EBITDA margin targeted at 30% by year end, 35% plus with API backward integration. Bavla facility can support INR800-1,000cr revenue at full utilization in 4-5 years without major capex. 178 dossiers submitted, 16 marketing authorizations received, targeting 100 plus MAs.

Likely market impact

Strong Q1 with 120% PAT growth and clear multi-year oncology scaling guidance. Margin expansion expected with API integration. Positive outlook.